Insider Selling: SOPHiA GENETICS (NASDAQ:SOPH) Insider Sells $17,433.00 in Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Philippe Menu sold 3,725 shares of the company’s stock in a transaction that occurred on Friday, April 10th. The stock was sold at an average price of $4.68, for a total transaction of $17,433.00. Following the completion of the transaction, the insider owned 272,996 shares in the company, valued at approximately $1,277,621.28. This represents a 1.35% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Philippe Menu also recently made the following trade(s):

• On Tuesday, April 14th, Philippe Menu sold 1,600 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.96, for a total transaction of $7,936.00.
• On Monday, April 13th, Philippe Menu sold 4,400 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.76, for a total transaction of $20,944.00.
• On Thursday, April 9th, Philippe Menu sold 1,931 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.74, for a total transaction of $9,152.94.
• On Wednesday, April 8th, Philippe Menu sold 2,800 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.84, for a total transaction of $13,552.00.
• On Tuesday, April 7th, Philippe Menu sold 2,400 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.87, for a total transaction of $11,688.00.
• On Monday, April 6th, Philippe Menu sold 2,700 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.85, for a total transaction of $13,095.00.
• On Thursday, March 19th, Philippe Menu sold 608 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.79, for a total transaction of $2,912.32.

SOPHiA GENETICS Trading Up 1.0%

Shares of NASDAQ SOPH opened at $5.12 on Friday. The company has a market cap of $350.67 million, a PE ratio of -10.04 and a beta of 1.04. The firm’s 50 day moving average price is $4.75 and its 200-day moving average price is $4.72. SOPHiA GENETICS SA has a 52-week low of $2.58 and a 52-week high of $5.70. The company has a debt-to-equity ratio of 1.01, a quick ratio of 1.84 and a current ratio of 1.96.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.08). The company had revenue of $21.71 million for the quarter, compared to the consensus estimate of $21.20 million. SOPHiA GENETICS had a negative net margin of 44.22% and a negative return on equity of 50.60%. On average, equities research analysts expect that SOPHiA GENETICS SA will post -0.96 EPS for the current fiscal year.

SOPHiA GENETICS News Summary

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: Strategic commercial win — Mount Sinai Health System will adopt SOPHiA GENETICS’ AI-powered SOPHiA DDM™ platform to support precision cancer care and genomic testing at a major NCI-designated center, which could drive recurring software volume and credibility with large U.S. health systems. Mount Sinai collaboration
• Positive Sentiment: Sector tailwind — coverage highlighting Mount Sinai’s use of AI to speed genomic testing reinforces demand for AI-driven genomics platforms like SOPHiA DDM, supporting adoption and long-term revenue potential. Healthcare IT News
• Positive Sentiment: Analyst interest — several firms have set $7.00 targets and issued buy opinions (e.g., Guggenheim, BTIG), giving investors an upside reference versus current levels.
• Neutral Sentiment: Insider selling activity — multiple insiders (CEO Jurgi Camblong, President Ross Muken and others) disclosed sales totaling tens of thousands of shares in mid-April. All trades were executed under pre-arranged Rule 10b5-1 plans and many were described as tax-withholding sales tied to vested awards, which reduces immediate governance concern but increases float. SEC Form 4 (example)
• Negative Sentiment: Underlying profitability risks — the company reported a March-quarter EPS miss (reported ($0.28) vs. consensus ($0.20)), with negative net margins and a substantial negative ROE. Analysts still expect FY losses (consensus around -0.96 EPS), highlighting ongoing path-to-profitability concerns that can cap multiple expansion. Earnings & metrics

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on SOPH shares. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Thursday, January 22nd. Guggenheim increased their price objective on shares of SOPHiA GENETICS from $6.00 to $7.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Finally, BTIG Research increased their price objective on shares of SOPHiA GENETICS from $7.00 to $8.00 and gave the company a “buy” rating in a research report on Wednesday. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $7.50.

Institutional Trading of SOPHiA GENETICS

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Savvy Advisors Inc. purchased a new stake in SOPHiA GENETICS during the third quarter valued at approximately $48,000. Squarepoint Ops LLC purchased a new stake in SOPHiA GENETICS during the third quarter valued at approximately $49,000. Perkins Capital Management Inc. purchased a new stake in shares of SOPHiA GENETICS in the fourth quarter worth $49,000. Quadrature Capital Ltd purchased a new stake in shares of SOPHiA GENETICS in the fourth quarter worth $54,000. Finally, XTX Topco Ltd purchased a new stake in shares of SOPHiA GENETICS in the fourth quarter worth $55,000. 31.59% of the stock is owned by hedge funds and other institutional investors.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.